Exhibit 10.32           Promissory Note, dated April 29, 2003, issued by Enhance
                        Biotech, Inc. to Buddy Young

                                 PROMISSORY NOTE

US$200,000.00                                         New York, New York
                                                      Dated: April  __, 2003

      FOR VALUE RECEIVED consisting of consulting services rendered for which
payment is due, the undersigned ("Obligor") promises to pay to the order of MR.
BUDDY YOUNG ("Payee") the aggregate principal sum of TWO HUNDRED THOUSAND
DOLLARS ($200,000.00), plus interest, on the terms and conditions that follow.

      1. Principal Payments. Payments of the principal amount of this Promissory
Note shall be made as follows:

Amount of Principal Payment               Date Payment Due

US$ 5,000               May 1st, 2003
US$ 5,000               June 1, 2003
US$ 5,000               July 1, 2003
US$ 5,000               August 1, 2003
US$ 5,000               September 1, 2003
US$ 5,000               October 1, 2003
US$60,000               November, 1 2003
US$ 8,000               December 1, 2003
US$ 8,000               January 1, 2004
US$ 8,000               February 1, 2004
US$ 8,000               March 1, 2004

<PAGE>


US$ 8,000               April 1, 2004
US$ 8,000               May 1, 2004
US$ 8,000               June 1, 2004
US$ 8,000               July 1, 2004
US$ 8,000               August 1, 2004
US$ 8,000               September 1, 2004
US$ 8,000               October 1, 2004
US$ 8,000               November 1, 2004
US$14,000               December 1, 2004

      2. Interest. The Note shall accrue interest on the unpaid principal amount
from time to time outstanding hereunder from the date hereof until all principal
has been repaid in full at an annual rate equal to two percent (2%) per annum.
Every payment of principal under this Promissory Note shall be made with payment
of all accrued but unpaid interest on such principal. Interest shall be computed
on the basis of a three hundred sixty (360) day year, for the actual number of
days elapsed.

            A. Any amount of principal hereunder which is not paid when due and,
to the extent permitted by applicable law, any overdue interest shall bear
interest at a rate per annum equal to the rate set forth in Section 2 hereof
plus three percent (3%) from five (5) days after the due date thereof (whether
at the stated maturity, by acceleration, or otherwise) until paid or reimbursed
in full (after as well as before judgment), payable on demand.

            B. In no event shall interest charged under this Note exceed the
highest rate permissible under any law which a court of competent jurisdiction
shall, in a final determination, deem applicable hereto. In the event that such
a court determines that the Payee has received interest and/or other payments
hereunder, or in connection with the loan evidenced by this Note in excess of
the highest rate permissible, the Payee shall promptly refund such excess
interest to the Obligor. Such refund may be credited as a reduction against
unpaid principal.

      3. Location of Payments; Certain Payment Dates. All payments (including
optional prepayments under section 3 hereof) to be made by the Obligor under
this Note shall be made not later than 5:00 p.m. Pacific Time, on the due date,
at 17337 Ventura Boulevard, Suite 224, Encino, CA 91316, or at such other place
or to such account as the Payee may designated to the Obligor in writing, in
lawful money of the United States of America and in immediately available funds.
Payments received by Payee after 5:00 p.m., Pacific Standard Time, will be
deemed to be received on the next business day. If any such payment becomes due
and payable on a Saturday, Sunday, legal holiday or other day on which
commercial banks in New York, New York or in the State of California are
authorized by law or regulation to close or are closed for business (a "Business
Day"), such due date shall be extended to the next succeeding business day and,
with respect to interest-bearing payments, interest shall continue to accrue at
the applicable rate during such extension and shall be payable on such due date
as so extended. Any payments made hereunder shall be applied first against costs
and expenses due hereunder; then against default interest if any; then against
interest due on the loan evidenced by this Note then outstanding; and thereafter
against the principal amount of the loan due and payable.

      4. Prepayment. This Promissory Note may be prepaid in full (but not in
part) at any time without premium or penalty, provided that any such prepayment
is made together with accrued interest to the date of such prepayment on the
amount prepaid.

      5. Certain Waivers. The undersigned Obligor waives demand, presentment,
notice of non-payment and notice of dishonor. No delay or omission on the part
of the Payee in exercising any right or remedy hereunder or with respect hereto
shall operate as waiver of such right or remedy or of any other right or remedy
hereunder or with respect hereto. Waiver on any one occasion by Payee shall not
be construed as a bar to or waiver of any such right or remedy on any future
occasion.

<PAGE>

      6. Default. Upon the occurrence of any one or more of the following
events, the Payee can declare a "Default" upon written notice to the Obligor:

            A. the Obligor shall fail to pay any principal or interest on this
Note when due, whether at maturity, by notice of prepayment or otherwise, and
such failure shall continue for five (5) business days after the the Obligor
shall have received written notice from Payee of such default;

            B. the Obligor shall fail to pay any money due under any other
agreement or document evidencing, securing, guaranteeing or otherwise relating
to indebtedness of the Obligor for borrowed money and such failure has a
material adverse effect on Obligor's financial condition, and such condition
shall continue for five (5) business days after the Obligor shall have received
written notice from the Payee of such default, the Payee may, upon two (2)
business days' written written notice to the Obligor, declare the unpaid
principal of and all accrued interest (but not any additional interest provided
for but not yet then due under Section ___ (__) payable under this Note to be
immediately due and payable, whereupon the same shall be and become immediately
due and payable;

            C. the breach of any covenants made herein by the Obligor, and such
failure shall continue for five (5) business days after the the Obligor shall
have received written notice from Payee of such default; or,

            D. The failure to complete the "Private Placement" (as such term is
defined in the Acquisition Agreement by and between Becor Communications, Inc.
and Enhance LifeSciences, Inc., dated as of February __, 2003 (the "Acquisition
Agreement")), as required by the Acquisition Agreement on or before the date
with is six (6) months after the "Closing" (as defined in the Acquisition
Agreement).

      7. Remedies. In the event that the Obligor declares a Default pursuant to
Section 6 of this Promissory Note, and such Default shall not have been cured as
provided herein, the Payee, at the Payee's option, may do the following:

            (a) The Payee shall have the right, upon five (5) days written
notice to the Obligor, to accept the resignations of Payee's then current Board
of Directors and to exercise the proxies given to Payee by shareholders of
Obligor to nominate and elect natural persons to fill the vacancies on the
Obligor's Board of Directors which were created by such resignations and to
nominate and elect such other members of the Board of Directors as Payee may
desire such that Payee's designees shall constitute the entire membership of the
Obligor's Board of Directors.

            (b) If the Payee should exercise the right described in
sub-paragraph (a) above, the Payee's exercise of such right shall be
conditionedl upon the Payee complying, and causing the Obligor to comply, with
sub-paragraphs (c) and (d) of this Section as promptly as practicable, time
being of the essence, and taking no other actions, and permitting Obligor to
take no other actions in respect of Obligor or its business or assets, until the
actions set forth in sub-paragraphs (c) and (d) are completed, except for such
actions as .are necessary in the reasonable opinion of Payee to preserve Obligor
and its business.

            (c) If the Payee should exercise the right described in
sub-paragraph (a) above, the Payee shall cause the Obligor, as promptly as
practicable, to effect the spin-off of all of the stock of the Enhance
Lifesciences, Inc. subsidiary (which company shall include all of its business
and assets as acquired by the Obligor pursuant to the Acquisition Agreement and
no liabilities or obligations other than those incurred by Obligor and Enhance
Lifesciences, Inc. prior to the exercise of the Payee's rights pursuant to
Section 7(a) of this Promissory Note) on a pro-rata basis to the shareholders of
Enhance Lifesciences, Inc. as they existed immediately prior to the signing of
the Acquisition Agreement, provided, however, that the original shareholders of
"BCI" (as such term is defined in the Acquisition Agreement), as the same were
constituted immediately prior to the consummation of the Closing under the
Acquisition Agreement, shall retain an aggregate shareholding of 10% in Enhance
Lifesciences, Inc. upon the spin-off and the original shareholders of Enhance
Lifesciences, Inc., as the same were constituted immediateloy prior to the
consummation of the Closing under the Acquisition Agreement, shall retain an
aggregate shareholding of 90% in Enhance Lifesciences, Inc. upon the spin-off.

<PAGE>

            (d) It is understood and agreed that upon completion of the spin-off
referred to in sub-paragraph (c) above, the Payee may cause the Obligor to
effect a reverse split of the stock of the Obligor and capitalization of the
remaining balance of this Promissory Note on such terms and conditions as the
Payee may deem to be reasonable and in the best interests of "BCI" following the
spin-off of Enhance Lifesciences, Inc., provided, however, that following any
initial reverse split, "BCI" and/or Payee shall cause "BCI" to issue that number
of shares necessary to provide the shareholders of Enhance Lifesciences, Inc. as
they existed immediately prior to the signing of the Acquisition Agreement and
on a pro-rata basis, with an aggregate total of not less than ten percent (10%)
of the issued and outstanding shares of "BCI" immediately following such reverse
split.

      8. Assignment. All covenants, agreements and undertakings in this
Promissory Note are binding upon the Obligor and the Payee and shall bind and
inure to the benefit of their permitted successors and permitted assigns.
Notwithstanding the foregoing, in no event may Payee assign this Promissory
Note, or any interest herein, without the prior written consent of Obligor.

      9. Governing Law; Jurisdiction and Venue. This AGREEMENT is governed by
and shall be construed in accordance with the internal laws of the State of
California without reference to its rules as to conflicts of law and each party
irrevocably submits to the exclusive jurisdiction of the United States District
Court for the Central District of California, for the purposes of any proceeding
arising out of or relating to this AGREEMENT, any other transaction contemplated
hereby or thereby, provided, however, that in the event the United States
District Court refuses to accept jurisdiction over the dispute, then the matter
shall be submitted to the exclusive jurisdiction of the Superior Court in and
for the County of Los Angeles, State of California, and it related courts. Each
party further agrees that service of any process, summons, notice or document by
U.S. registered mail to such party's respective address set forth above shall be
effective service of process for any proceeding.

      10. Waiver of Jury Trial. THE PAYEE AND THE OBLIGOR HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY
IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN
CONNECTION WITH THIS PROMISSORY NOTE.

      11. Expenses and Fees. All fees, costs and expenses of every kind and
nature, including but not limited to the reasonable attorneys' fees and legal
expenses, incurred by Payee in connection with the collection, administration,
or enforcement of its rights under this Promissory Note or in defending or
prosecuting any actions or proceedings arising out of or related to any amounts
due to Payee under this Promissory Note shall be borne and paid by the Obligor
upon written demand by the Payee delivered with appropriate supporting
documentation and, until paid, shall be added to the amounts due hereunder and
bear interest at the rate of interest applicable to payments of principal under
this Promissory Note; provided, that Payee shall be entitled to no such
reimbursement in the event and to the extent that any such claim or action shall
be determined in favor of Obligor.

      12. Third Party Beneficiaries. To the extent of enforcing the provisions
of Section 7 of this Promissory Note pertaining to the spin-off of Enhance
Lifesciences, Inc. and the limitation on reverse stock splits and capitalization
of this Promissory Note, Lee Cole, as representative of the shareholders of
Enhance Lifesciences, Inc. (as the same shall have been constituted immediately
prior to the consummation of the Closing) shall be deemed to be the third party
beneficiary entitled to enforce those provisions of this Promissory Note.

             [the balance of this page is intentionally left blank]

<PAGE>

      13. Entire Agreement. This Promissory Note sets forth the entire agreement
of the parties with respect to the subject matter hereof and thereof,
superseding and replacing any agreement or understanding that may have existed
between the parties prior to the date hereof in respect to such subject matter.

            IN WITNESS WHEREOF, this Promissory Note has been executed and
delivered on the date first specified above by the duly authorized
representative of the Obligor.

                                    ENHANCE LIFESCIENCES, INC.


                                    _________________________

                              By:   Name:____________________

                                    Title:  President